moneyheap
NVCR · Analysis updated Nov 10, 2026, 6:00 PM ET
Why is NovoCure Limited Ordinary Shares (NVCR) stock moving?
NVCR closed at $11.81 on Nov 10, its lowest close in the 30-day window and down about 11% from $13.28 on Nov 6, with an intraday low of $11.56. The drop follows the FDA's Not Approvable letter for Optune Mya in brain metastases from NSCLC, announced Nov 9. The FDA cited uncertain clinical benefit, not safety, and Novocure plans to meet the agency about options that might avoid new clinical studies, with no assurance of success. Volume was elevated on Nov 9 (2.8M shares) and Nov 10 (1.9M), against a baseline near 1.1-1.6M, which confirms the selling. Fundamentals were strong just before this: Q3 2026 revenue of $193.4M beat the $182.2M estimate, EPS of $(0.09) beat $(0.24), and FY2026 sales guidance was raised to $736M-$743M. The stock still fell 7.5% on Oct 29 from $14.17 to $13.11 on 5.96M shares, then recovered to $14.61 by Nov 4 before the FDA news. Analyst reaction is split: Wells Fargo cut to Equal-Weight with a $15 target, Evercore cut to Outperform with a $20 target, and Wedbush kept Neutral with a $19 target, while Ladenburg Thalmann kept Buy and raised its target to $31. The average 12-month target was $22.2 as of Nov 5. The Japan approval of Optune Pax for pancreatic cancer (Sep 15) and the Verastem pancreatic collaboration (Oct 28) add some diversification, but the Optune Mya setback is the dominant near-term issue.
News behind the analysis
- Novocure Receives FDA 'Not Approvable' Letter for Optune MyaNovocure said the FDA issued a Not Approvable letter on its PMA for Optune Mya in brain metastases from NSCLC. The FDA cited uncertainty about clinical benefit and raised no safety concerns.
- Novocure Stock Slips After FDA Rejects Its Cancer Treatment DeviceShares slipped after the FDA's Not Approvable letter for Optune Mya. The letter cited unclear clinical benefit while finding no safety issues.
- Novocure Receives Not Approvable Letter From FDA In Response To PMA Application For Optune Mya For Treatment Of Adult Patients With Brain Metastases From Non-Small Cell Lung Cancer Following Stereotactic RadiationNovocure is evaluating the FDA feedback and plans to meet the agency to explore options that would not require additional clinical studies. The company gave no assurance those talks will succeed.
- Ladenburg Thalmann Maintains Buy on NovoCure, Raises Price Target to $31Ladenburg Thalmann kept its Buy rating and raised its price target to $31 after the FDA letter. It is the highest target among the recent analyst notes.
- Wedbush Maintains Neutral on NovoCure, Lowers Price Target to $19Wedbush kept a Neutral rating and cut its price target to $19. The move follows the FDA setback for Optune Mya.
- Novocure Limited 12-Month Price Target Raised to $22.2The average 12-month analyst price target rose from $21.33 to $22.2, implying roughly 52% upside at the time of the report.
- NovoCure Raises FY2026 Sales Guidance from $710.000M-$725.000M to $736.000M-$743.000M vs $725.814M EstNovocure lifted full-year 2026 sales guidance to $736M-$743M, above the $725.8M consensus estimate. The raise came with its Q3 report.
- NovoCure Q3 EPS $(0.09) Beats $(0.24) Estimate, Sales $193.399M Beat $182.233M EstimateNovocure reported Q3 2026 EPS of $(0.09) against a $(0.24) estimate and sales of $193.4M against $182.2M expected. Both figures beat consensus.
- Evercore ISI Group Maintains Outperform on NovoCure, Lowers Price Target to $20Evercore ISI kept its Outperform rating and cut its price target from $23 to $20. The cut came after the Q3 report.
- Novocure Enters Into Clinical Trial Collaboration And Supply Agreement With Verastem Oncology To Evaluate Use Of Novocure's TTFields Therapy With Chemotherapy And VS-7375 To Treat Locally Advanced Pancreatic CancerNovocure signed a clinical trial collaboration and supply agreement with Verastem Oncology to test TTFields with chemotherapy and VS-7375 in locally advanced pancreatic cancer. The deal extends its pancreatic cancer program.
About NovoCure Limited Ordinary Shares
Novocure is an oncology company based in Baar, Switzerland, that sells Tumor Treating Fields (TTFields), a wearable device that sends electric fields into the body to disrupt cancer cell division. Its products are approved in certain countries for glioblastoma (Optune Gio), lung cancer and mesothelioma (Optune Lua), and, since 2026, locally advanced pancreatic cancer (Optune Pax).
How it makes money
Novocure earns most of its revenue from monthly charges for patients using its devices, paid mostly by insurers and national health systems. Optune Gio for brain cancer brings in the large majority of sales, about 4,500 of roughly 4,800 active patients in early 2026. Optune Lua and the newly launched Optune Pax add a small but growing share. It also earns a few million dollars a quarter through its Greater China partnership with Zai Lab. In early 2026 the company guided to roughly $690–710 million in 2026 revenue, with adjusted EBITDA (a rough measure of operating cash profit) near breakeven or slightly negative.
What usually moves NVCR
- Clinical trial readouts (e.g., TRIDENT, PANOVA-4, KEYNOTE D58)
- FDA and international regulatory decisions
- Insurance reimbursement and coverage wins
- Active patient growth on Optune Gio, Lua and Pax
- Cash burn and path to profitability